For the Inventor, By the Inventor

Enter assignee name

Vienna, Austria

Valneva Austria Gmbh

USPTO Granted Patents = 46

CIPO Patents = 1

EPO Patents = 18

Trademarks = 12

Forward Citations = 139

Loading Chart...

Loading Chart...

84 inventors (with patents filed for the assignee):

Robert Schlegl (18 out of 26 patents)

Michael Weber (15 out of 24 patents)

Andreas Meinke (15 out of 45 patents)

4. Urban Lundberg (12 out of 20 patents)

5. Jürgen Heindl-Wruss (10 out of 18 patents)

6. Wolfgang Schüler (10 out of 12 patents)

7. Markus Hanner (9 out of 19 patents)

8. Jana Barbero Calzado (8 out of 13 patents)

9. Mario Nebenführ (8 out of 16 patents)

10. Benjamin Wizel (8 out of 8 patents)

11. Jing-Hui Tian (6 out of 21 patents)

12. Larry R Ellingsworth (6 out of 6 patents)

13. David Flyer (6 out of 8 patents)

14. Steven R Fuhrmann (6 out of 7 patents)

15. Stefanie Kluepfel-Stahl (6 out of 6 patents)

Core Competencies:

OspA Polypeptides

Zika Virus Vaccine

SARS-CoV-2 Vaccine

Aluminum Compounds

Immunostimulatory Oligodeoxynucleotides

OprF/I Fusion Proteins

IC31 Nanoparticles

Vaccine Composition

Attenuated Live Vaccines

Flaviviridae Mutants

Toxin A Proteins

Toxin B Proteins

46 patents: Sort by Forward Citations

1. 12331084 - Multivalent OspA polypeptides and methods and uses relating thereto (2025-06-17),

2. 12324831 - Isolated polypeptide of the toxin A and toxin B proteins ofand uses thereof (2025-06-10),

3. 12195501 - Mutant fragments of OspA and methods and uses relating thereto (2025-01-14),

4. 12102673 - Zika virus vaccine (2024-10-01),

5. 12018054 - Multivalent OspA polypeptides and methods and uses relating thereto (2024-06-25),

6. 12005111 - Zika virus vaccine (2024-06-11),

7. 11951163 - Zika virus vaccine (2024-04-09),

8. 11684669 - CpG-adjuvanted SARS-CoV-2 virus vaccine (2023-06-27),

9. 11572392 - Mutant fragments of OspA and methods and uses relating thereto (2023-02-07),

10. 11524064 - Zika virus purification (2022-12-13),

11. 11478540 - Isolated polypeptide of the toxin A and toxin B proteins ofand uses thereof (2022-10-25),

12. 11466058 - Mutant fragments of OspA and methods and uses relating thereto (2022-10-11),

13. 11357844 - Isolated polypeptide of the toxin A and toxin B proteins ofand uses thereof (2022-06-14),

14. 11331382 - Zika virus purification (2022-05-17),

15. 11219681 - Zika virus vaccine (2022-01-11),

Valneva Austria GmbH is a global biotech company that specializes in the development, production, and marketing of vaccines. With a focus on preventing diseases, their diverse portfolio includes vaccines for prevention and treatment of infectious diseases. Valneva prides itself on advancing health through innovative research and development, ensuring the highest quality products to improve global public health.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

46 Patents

#16 in Vienna

#82 in Austria

#14,712 in the World

Vienna, Austria

Valneva Austria Gmbh

Forward Citations = 139

84 inventors:

Robert Schlegl (18 out of 26 patents)

Michael Weber (15 out of 24 patents)

Andreas Meinke (15 out of 45 patents)

4. Urban Lundberg (12 out of 20 patents)

5. Jürgen Heindl-Wruss (10 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…